Fraietta et al. analyzed the genomic, phenotypic, and functional profiles of 41 patients with advanced, heavily pretreated, and high-risk Chronic Lymphocytic Leukemia (CLL) treated with CD19-CAR T cell therapy and found that complete-responding patients were characterized by memory-like T cells prior to treatment, such as CD27+ CD45RO− CD8+ T cells [30]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.